Viking Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $13.7M | $9.0M | $7.0M | $22.2M |
| SG&A Expense | $5.3M | $4.8M | $5.0M | $1.2M |
| Operating Income | $-19.1M | $-13.8M | $-12.0M | $-23.5M |
| Operating Margin | — | — | — | — |
| Interest Expense | — | — | — | — |
| Pretax Income | — | — | — | — |
| Income Tax Expense | $0 | $0 | — | — |
| Net Income | $-20.6M | $-14.7M | $-23.4M | $-21.9M |
| Net Margin | — | — | — | — |
| EPS (Basic) | $-0.79 | $-0.90 | $-3.68 | $-5.23 |
| EPS (Diluted) | $-0.79 | $-0.90 | $-3.68 | $-5.23 |
| Shares Outstanding (Basic) | 35.8M | 20.8M | 9.7M | 6.0M |
| Shares Outstanding (Diluted) | 35.8M | 20.8M | 9.7M | 6.0M |
| Dividends Per Share | — | — | — | — |